Intratumoral Hemorrhage in HCC Patients Under Atezolizumab-Bevacizumab Therapy

107 consecutive patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab between October 2020 and March 2022. The dataset likely contains clinical and radiological data from a single-center retrospective cohort study investigating intratumoral hemorrhage incidence, risk factors, and prognostic significance. The author is figshare admin karger, and the material was last updated in April 2026.

Use Cases

• Analyze incidence of intratumoral hemorrhage based on contrast-enhanced CT imaging criteria.
• Investigate correlation between tumor size and hemorrhage risk based on tumor diameter measurements.
• Evaluate progression-free survival outcomes based on RECIST 1.1 and mRECIST criteria.
• Study temporal changes in hemorrhage grade based on serial CT examinations.

Strengths

• 107 patient records from a defined cohort treated between October 2020 and March 2022.
• Radiological findings are defined with specific criteria for intratumoral hemorrhage.
• Clinical outcomes include progression-free survival analyzed per two standard criteria (RECIST 1.1 and mRECIST).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect bias inherent to a single-center retrospective study.

Provenance

Source

figshare

Collection Method

Single-center retrospective cohort study.

Time Range

October 2020 to March 2022.

Freshness

Last updated 2026-04-27 05:55:13; freshness should be verified.